News of Note—Merck, FluGen and more

In this week's news of note, Merck posted a Gardasil sales increase. (NS Newsflash/CC BY 2.0)

Here is some other vaccine news of note for the week.

> Merck's Gardasil sales grew 24% in the first quarter to $660 million. Release

> FluGen's CEO said the company will consider seeking funding from a new Gates Foundation universal flu vaccine challenge. Xconomy article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Rational Vaccines, a company that has come under fire for unregulated vaccine testing, removed a lawsuit to federal court in Illinois. Law360 article

> Pfizer's Prevnar sales slipped 1% to $1.38 billion in the first quarter. Release (PDF)


Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.